Inflectra's Label Won't Depend On Continuing Study In IBD

Advisory committee members anxious about extrapolating Remicade's inflammatory bowel disease indications to biosimilar Inflectra wanted to wait for an ongoing trial, but FDA says idea misses the point of biosimilar pathway.